Norman David Eansor
Net Worth
Last updated:
What is Norman David Eansor net worth?
The estimated net worth of Mr. Norman David Eansor is at least $31,993,549 as of 16 Nov 2021. He owns shares worth $1,522,180 as insider, has earned $14,471,369 from insider trading and has received compensation worth at least $16,000,000 in Bio-Techne Corporation.
What is the salary of Norman David Eansor?
Mr. Norman David Eansor salary is $1,600,000 per year as Advisor in Bio-Techne Corporation.
How old is Norman David Eansor?
Mr. Norman David Eansor is 64 years old, born in 1961.
What stocks does Norman David Eansor currently own?
As insider, Mr. Norman David Eansor owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | Advisor | 27,777 | $54.8 | $1,522,180 |
What does Bio-Techne Corporation do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Norman David Eansor insider trading
Bio-Techne Corporation
Mr. Norman David Eansor has made 11 insider trades between 2015-2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 32,933 units of TECH stock on 5 Feb 2021. As of 16 Nov 2021 he still owns at least 27,777 units of TECH stock.
Bio-Techne key executives
Bio-Techne Corporation executives and other stock owners filed with the SEC:
- Mr. Charles R. Kummeth (65) Chief Executive Officer, Pres & Director
- Mr. James T. Hippel (54) Executive Vice President of Fin. & Chief Financial Officer
- Mr. Kim Kelderman (58) Pres of Diagnostics & Genomics
- Mr. Norman David Eansor (64) Advisor
- Ms. Brenda S. Furlow J.D. (67) Executive Vice President, Gen. Counsel, Sec. & Chief Compliance Officer